About Us

A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). Inversago’s technology addresses limits associated with first generation CB1 blockers, allowing the company to exploit their full medical potential.

News and Events

July 25, 2018 - Inversago Pharma receives $7 million in series A financing


July 25, 2018 - Inversago Pharma receives $7 million in series A financing